TY - JOUR
T1 - Uterine cancer among Asian Americans – Disparities & clinical characteristics
AU - Johnson, Caitlin R.
AU - Liao, Cheng I.
AU - Tian, Chunqiao
AU - Richardson, Michael T.
AU - Duong, Kim
AU - Tran, Nathan
AU - Winkler, Stuart S.
AU - Kapp, Daniel S.
AU - Darcy, Kathleen
AU - Chan, John K.
N1 - Publisher Copyright:
© 2024 Elsevier Inc.
PY - 2024/3
Y1 - 2024/3
N2 - Objective: To evaluate the patterns and trends of uterine cancer among Asian subgroups living in the U.S. Methods: Data were obtained from United States Cancer Statistics (2001–2017), National Cancer Database (2004–2015), and World Population Review (2023). SEER*Stat version 8.3.9.2, Joinpoint regression program 4.9.0.0, and SAS v 9.4 were employed for statistical analysis. Results: Based on data from 778,891 women in the United States Cancer Statistics database, Asians had a 3.4-fold higher rate of incident uterine cancer compared to White populations (2.14% vs. 0.63%; p < 0.001). Using the National Cancer Database, 7,641 Asian women from six subgroups were analyzed: Filipino, Korean, Indian/Pakistani, Vietnamese, Chinese, and Japanese. Indian and Pakistani women had the greatest increase in the proportion of cancer diagnoses (5.0% to 14.4%; p = 0.0003). Additionally, Indian and Pakistani patients had higher comorbidity scores while Koreans had the lowest (22.7% vs. 10.7%, p < 0.0001). Regarding stage of disease, 25.3% of Filipinos presented with advanced stage disease compared to 19.2% of Indians and Pakistanis (p = 0.0001). Furthermore, Filipinos had the highest proportion of non-endometrioid cancers at 18.4% compared to other subgroups (p = 0.0003). Using the World Population Review, female obesity was highest in Pakistan (8.6%) and the Philippines (7.5%) and lowest in Vietnam (2.6%). Conclusion: Uterine cancer incidence increased at higher rates among Asians compared to White populations. Specifically, Indian and Pakistani uterine cancer patients were more likely to have higher comorbidity rates and Filipino patients had more advanced stage cancer with non-endometrioid histologies than other Asian subgroups. Further research is warranted to better understand these trends.
AB - Objective: To evaluate the patterns and trends of uterine cancer among Asian subgroups living in the U.S. Methods: Data were obtained from United States Cancer Statistics (2001–2017), National Cancer Database (2004–2015), and World Population Review (2023). SEER*Stat version 8.3.9.2, Joinpoint regression program 4.9.0.0, and SAS v 9.4 were employed for statistical analysis. Results: Based on data from 778,891 women in the United States Cancer Statistics database, Asians had a 3.4-fold higher rate of incident uterine cancer compared to White populations (2.14% vs. 0.63%; p < 0.001). Using the National Cancer Database, 7,641 Asian women from six subgroups were analyzed: Filipino, Korean, Indian/Pakistani, Vietnamese, Chinese, and Japanese. Indian and Pakistani women had the greatest increase in the proportion of cancer diagnoses (5.0% to 14.4%; p = 0.0003). Additionally, Indian and Pakistani patients had higher comorbidity scores while Koreans had the lowest (22.7% vs. 10.7%, p < 0.0001). Regarding stage of disease, 25.3% of Filipinos presented with advanced stage disease compared to 19.2% of Indians and Pakistanis (p = 0.0001). Furthermore, Filipinos had the highest proportion of non-endometrioid cancers at 18.4% compared to other subgroups (p = 0.0003). Using the World Population Review, female obesity was highest in Pakistan (8.6%) and the Philippines (7.5%) and lowest in Vietnam (2.6%). Conclusion: Uterine cancer incidence increased at higher rates among Asians compared to White populations. Specifically, Indian and Pakistani uterine cancer patients were more likely to have higher comorbidity rates and Filipino patients had more advanced stage cancer with non-endometrioid histologies than other Asian subgroups. Further research is warranted to better understand these trends.
KW - Asian Americans
KW - Disparities
KW - Uterine cancer
UR - http://www.scopus.com/inward/record.url?scp=85183189857&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2023.12.023
DO - 10.1016/j.ygyno.2023.12.023
M3 - Article
C2 - 38246043
AN - SCOPUS:85183189857
SN - 0090-8258
VL - 182
SP - 24
EP - 31
JO - Gynecologic Oncology
JF - Gynecologic Oncology
ER -